Eng-Huat Tan

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.1K citations

Oncology, Phase 2B, Pathology +8

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma

Anne W.M. Lee, Stewart Y. Tung, Anthony T.�C. Chan et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 157 citations

Npc-9902 Trial, Medicine, Metronomic Therapy +9

A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma

Anne W.M. Lee, Stewart Y. Tung, Anthony T.�C. Chan et al. · Radiotherapy and Oncology · 2010 · 108 citations

Surgical Oncology, Locally-advanced Nasopharyngeal Carcinoma, Medicine +8

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy

Maciej Krzakowski, Rodryg Ramlau, Jacek Jassem et al. · Journal of Clinical Oncology · 2010 · 75 citations